Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Cue Biopharma, Inc. (CUE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/25/2023 |
8-K
| Quarterly results |
| 11/15/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Form of Pre-Funded Warrant to Purchase Common Stock to be issued pursuant to the Securities Purchase Agreement",
"Form of Warrant to Purchase Common Stock or Pre-Funded Warrant to be issued pursuant to the Securities Purchase Agreement",
"Form of Securities Purchase Agreement, by and among the Company and the other parties thereto",
"Registration Rights Agreement, by and among the Company and the other parties thereto",
"Cue Biopharma Announces $30 Million Private Investment in Public Equity Financing BOSTON, Nov. 14, 2022 — Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it has entered into securities purchase agreements with certain accredited investors for a $30 million private investment in public equity financing. The PIPE financing included a life sciences-focused investment fund that is a new investor in the company as well as participation from other new and existing investors. Piper Sandler & Co. acted as lead placement agent and Public Ventures LLC acted as co-placement agent to Cue Biopharma for the PIPE financing. In..." |
|
| 06/22/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 03/30/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/18/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/15/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/01/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 06/14/2021 |
8-K
| Quarterly results |
| 03/18/2021 |
8-K
| Quarterly results |
| 11/19/2020 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 09/17/2020 |
8-K
| Appointed a new director |
| 08/24/2020 |
8-K
| Quarterly results |
| 07/15/2020 |
8-K
| Quarterly results |
| 06/26/2020 |
8-K
| Quarterly results |
| 06/22/2020 |
8-K
| Quarterly results |
| 06/05/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/19/2020 |
8-K
| Quarterly results|
Docs:
|
"Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights CAMBRIDGE, Mass., May 19, 2020 — Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the first quarter 2020. “We have successfully maintained momentum in meeting our business goals and clinical trial objectives for the first quarter and early second quarter of 2020, despite the rapid onset of COVID-19 and the many challenges it has presented,” said Daniel Passeri, chief executive officer of Cue Biopharma. “I am grateful for the dedication of the Cue Biopharma team during this pandemic as we continue to..." |
|
| 03/27/2020 |
8-K
| Quarterly results |
| 03/17/2020 |
8-K
| Quarterly results |
| 03/02/2020 |
8-K
| Quarterly results |
| 02/10/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 10/09/2019 |
8-K
| Quarterly results |
| 10/07/2019 |
8-K
| Quarterly results |
| 08/06/2019 |
8-K
| Quarterly results |
| 06/05/2019 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 11/08/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat... |
| 08/03/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/12/2018 |
8-K
| Quarterly results |
| 06/26/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/25/2018 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 06/12/2018 |
8-K
| Submission of Matters to a Vote of Security Holders |
|
|
|